Clinical trial results performed in Canada and France using mFOLFIRINOX have shown that patients who undergo surgical removal of pancreatic cancer cells lived on average, 20 months longer than those who received gemicitabine. – Global News VIEW...
Pancreatic Cancer Canada is pleased to welcome Dr. Anish Kirpalani as the new Chair of the organization. Dr. Kirpalani served as a member of the Medical Advisory Board before joining the Board of Directors in 2015 and has been a leader in moving our research and...
Challenges for Small Charities: Pancreatic Cancer Canada joins a panel discussion in response to The Toronto Foundation’s latest Vital Signs Report – The Agenda with Steve Paikin (TVO) FULL...
Recent Comments